AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24282229 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (40 mg, 3 times per day)
Number of subjects: 35
Study 24282229 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-appearing tablets)
Number of subjects: 35
Study 21106284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session video-based, small group, cognitive-behavioral, HIV prevention intervention
Number of subjects: 346
Study 21106284 — intervention group
Group type: COMPARATOR
Intervention: 5-session video-based, contact-matched, HIV education control condition
Number of subjects: 346
Study 19143751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 48
Study 19143751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/day
Number of subjects: 48
Study 19143751 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with pravastatin)
Number of subjects: 48
Study 17695377 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 3552
Study 15197285 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychosocial treatment (comprehensive intervention with counseling, support, and consultation)
Number of subjects: 320
Study 15197285 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study 15197285 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychosocial treatment
Number of subjects: 320
Study 11773290 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy (including chemotherapy and tamoxifen)
Number of subjects: 10000
Study 9613308 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 30
Study 9613308 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 30
Study 8293412 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 259
Study 8293412 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide-dexamethasone cocktail
Number of subjects: 259
Study 2657424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal infusion of baclofen
Number of subjects: 20
Study 29750023 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL training
Number of subjects: 87
Study 29750023 — intervention group
Group type: COMPARATOR
Intervention: Multicomponent aerobic and strength exercise training
Number of subjects: 87
Study 29750023 — intervention group
Group type: COMPARATOR
Intervention: Combined ADL and exercise training
Number of subjects: 87
Study 29750023 — intervention group
Group type: COMPARATOR
Intervention: ADL training, multicomponent aerobic and strength exercise training, combined ADL and exercise training
Number of subjects: 87
Study 28877756 — intervention group
Group type: EXPERIMENTAL
Intervention: Jigsaw puzzle group
Number of subjects: 100
Study 28877756 — intervention group
Group type: COMPARATOR
Intervention: Cognitive health counseling group
Number of subjects: 100
Study 25790022 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation (650 mg of eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 79
Study 25790022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g of margarine daily without EPA/DHA)
Number of subjects: 79
Study 25790022 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation
Number of subjects: 79
Study 23639186 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-positive for at least one anxiety disorder (n=114)
Number of subjects: 250
Study 23639186 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of screen-positive anxiety conditions (1, 2, ≥3)
Number of subjects: 250
Study 23639186 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-positive anxiety conditions after adjusting for major depression
Number of subjects: 250
Study 21427155 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking exercise training (TWET)
Number of subjects: 60
Study 21427155 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground walking exercise training (OWET)
Number of subjects: 60
Study 21427155 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy rehabilitation (Control)
Number of subjects: 60
Study 18499184 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 U intradetrusor injection)
Number of subjects: 43
Study 18499184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 16513663 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PPCI)
Number of subjects: 7743
Study 16513663 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis (FL)
Number of subjects: 7743
Study 12920410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 0
Study 12920410 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20 mg/d)
Number of subjects: 0
Study 10966968 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin
Number of subjects: 34
Study 10966968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 34
Study 10966968 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug administration
Number of subjects: 34
Study 10187002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tramadol
Number of subjects: 142
Study 10187002 — intervention group
Group type: COMPARATOR
Intervention: Control (no tramadol)
Number of subjects: 142
Study 7825505 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% S-1033 solution
Number of subjects: 6
Study 7825505 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% S-1033 solution
Number of subjects: 6
Study 7825505 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% S-1033 solution (multiple-dose study)
Number of subjects: 6
Study 7825505 — intervention group
Group type: COMPARATOR
Intervention: Vehicle solution (control)
Number of subjects: 6
Study 3344931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk formula feeding before normal breastfeeding (n = 112)
Number of subjects: 216
Study 3344931 — intervention group
Group type: COMPARATOR
Intervention: Breastmilk feeding (n = 104)
Number of subjects: 216
Study 3344931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk formula feeding (n = 112)
Number of subjects: 216
Study 29270836 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP block (20 ml of ropivacaine 0.2%)
Number of subjects: 8
Study 29270836 — intervention group
Group type: EXPERIMENTAL
Intervention: ISP block (20 ml of ropivacaine 0.2%)
Number of subjects: 8
Study 28532529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counselling intervention (exclusive breast-feeding until 6 months, continued breast-feeding supplemented by protein-, lipid-, and carbohydrate-rich foods until age 2 years)
Number of subjects: 339
Study 28532529 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine feeding advice)
Number of subjects: 339
Study 28532529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counselling intervention
Number of subjects: 339
Study 28532529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 339
Study 26284410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg intravenously before anesthetic induction)
Number of subjects: 280
Study 26284410 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 280
Study 23124783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 714
Study 23124783 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 714
Study 20805297 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + IAST
Number of subjects: 40
Study 20805297 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 40
Study 18484560 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (n=16)
Number of subjects: 21
Study 18484560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline; n=5)
Number of subjects: 21
Study 17699258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose RATG (0.5 mg/kg per d) plus basiliximab (20 mg 4 d apart)
Number of subjects: 33
Study 17699258 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose RATG (2 mg/kg per d)
Number of subjects: 33
Study 12729882 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 65
Study 12729882 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 65
Study 11115442 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol, 50 microg bid
Number of subjects: 80
Study 11115442 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol, 50 microg, plus fluticasone propionate, 250 microg bid
Number of subjects: 80
Study 11115442 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol, 50 microg, plus fluticasone propionate, 500 microg bid
Number of subjects: 80
Study 11115442 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol, 50 microg, plus titrated theophylline bid
Number of subjects: 80
Study 9099188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram 1 alpha (OH)D3 daily + 300 mg elemental calcium
Number of subjects: 64
Study 9099188 — intervention group
Group type: COMPARATOR
Intervention: Inactive placebo + 300 mg elemental calcium
Number of subjects: 64
Study 8232358 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide at a starting dose of 2,400 mg/day, increased to a maximum of 4,800 mg/day
Number of subjects: 10
Study 3552455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (5%) spray
Number of subjects: 76
Study 3552455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinchocaine (2%) spray
Number of subjects: 76
Study 3552455 — intervention group
Group type: COMPARATOR
Intervention: Water-only placebo spray
Number of subjects: 76
Study 31209271 — intervention group
Group type: EXPERIMENTAL
Intervention: Starved treatment (no food)
Number of subjects: 84
Study 31209271 — intervention group
Group type: COMPARATOR
Intervention: Fed treatment (ad libitum access to food)
Number of subjects: 84
Study 31209271 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (second study)
Number of subjects: 84
Study 31209271 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol consumption (second study)
Number of subjects: 84
Study 29331959 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 20
Study 29331959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27038045 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Surgical Exercise Training (PreSET) - endurance and strength training
Number of subjects: 30
Study 27038045 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 25071343 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (LDT, 600 mg/d)
Number of subjects: 52
Study 25071343 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM, 100 mg/d)
Number of subjects: 52
Study 25071343 — intervention group
Group type: COMPARATOR
Intervention: Both groups (LDT and LAM)
Number of subjects: 52
Study 24304478 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-weighing twice a day with daily target setting and feedback (group 2)
Number of subjects: 60
Study 24304478 — intervention group
Group type: COMPARATOR
Intervention: Self-weighing once a day (group 1)
Number of subjects: 60
Study 20679147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified drinking water with 7.5 mg of elemental iron per liter (group B)
Number of subjects: 0
Study 20679147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified drinking water with 10 mg of elemental iron per liter (group C)
Number of subjects: 0
Study 20679147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified drinking water with 5 mg of elemental iron per liter (group A)
Number of subjects: 0
Study 20679147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Bixa orellana) (group D)
Number of subjects: 0
Study 18806533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (6 mg infusions administered on each of 3 days)
Number of subjects: 10
Study 18806533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 10
Study 15995051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with tympanostomy tubes
Number of subjects: 217
Study 15995051 — intervention group
Group type: COMPARATOR
Intervention: Tympanostomy tubes only (Control)
Number of subjects: 217
Study 15995051 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 217
Study 12689976 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling on physical activity (green prescription programme)
Number of subjects: 878
Study 12689976 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 878
Study 10569217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (PerMamma Abbott) providing 20mg zinc sulfate, 2mg copper sulfate, and 116 microg potassium iodide.
Number of subjects: 32
Study 10569217 — intervention group
Group type: COMPARATOR
Intervention: Traditional Italian diet without vitamin and mineral supplements.
Number of subjects: 32
Study 8724709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (LDD)
Number of subjects: 0
Study 8724709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1860094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg once daily (increased to 20 mg if needed)
Number of subjects: 80
Study 1860094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1860094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 80
Study 6352643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 55
Study 6352643 — intervention group
Group type: COMPARATOR
Intervention: Penicillin and Gentamicin
Number of subjects: 55
Study 30997967 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 30997967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27993381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction (under 100 mEq sodium diet) in Study A
Number of subjects: 0
Study 27993381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction (under 100 mEq sodium diet) in Study B
Number of subjects: 0
Study 25642682 — intervention group
Group type: EXPERIMENTAL
Intervention: physical practice + PETTLEP imagery (PP+PI)
Number of subjects: 36
Study 25642682 — intervention group
Group type: COMPARATOR
Intervention: physical practice + traditional imagery (PP+TI)
Number of subjects: 36
Study 25642682 — intervention group
Group type: COMPARATOR
Intervention: physical practice only (PP)
Number of subjects: 36
Study 25202068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy followed by surgical excision
Number of subjects: 10
Study 25202068 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision alone
Number of subjects: 10
Study 22459448 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview
Number of subjects: 889
Study 22459448 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview with booster
Number of subjects: 889
Study 22459448 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 889
Study 20879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 301
Study 20879046 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 301
Study 20879046 — intervention group
Group type: COMPARATOR
Intervention: Eccentric group of both SES and PES
Number of subjects: 301
Study 17619207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at specific points (colon 4 bilateral, liver 3 bilateral, urinary bladder 23 bilateral, gall bladder 25 contralateral to the stone, circulation 6 bilateral, Ren Mai)
Number of subjects: 102
Study 17619207 — intervention group
Group type: COMPARATOR
Intervention: Analgesics (50 mg pethidine and 10 mg diazepam)
Number of subjects: 102
Study 15899018 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmandibular implant-retained overdentures
Number of subjects: 60
Study 15899018 — intervention group
Group type: EXPERIMENTAL
Intervention: Four endosseous implants following augmentation of the mandible
Number of subjects: 60
Study 15899018 — intervention group
Group type: EXPERIMENTAL
Intervention: Four short endosseous implants
Number of subjects: 60
Study 15899018 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-assessed masticatory function (before treatment)
Number of subjects: 60
Study 12089368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous blood pressure control (<120/80 mmHg)
Number of subjects: 75
Study 12089368 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (135-140/85-90 mmHg)
Number of subjects: 75
Study 12089368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous blood pressure control
Number of subjects: 75
Study 12089368 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 75
Study 9583839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first 60 days)
Number of subjects: 9
Study 9583839 — intervention group
Group type: COMPARATOR
Intervention: Small supplement (0.93 micromol beta‐carotene/d, first 60 days)
Number of subjects: 9
Study 9583839 — intervention group
Group type: EXPERIMENTAL
Intervention: Small supplement (0.93 micromol beta‐carotene/d, days 61-120)
Number of subjects: 9
Study 9583839 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger mixed carotenoid supplement (6.16 micromol beta‐carotene/d, days 101-120)
Number of subjects: 9
Study 7643295 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐report California Psychological Inventory
Number of subjects: 215
Study 2565105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate
Number of subjects: 11
Study 2565105 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 11
Study 565216 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (Semet‐Se) 100 micrograms/day for 10-11 weeks
Number of subjects: 24
Study 565216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (selenite‐Se) 100 micrograms/day for 10-11 weeks
Number of subjects: 24
Study 565216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish (mackerel) selenium (fish‐Se) 65 micrograms/day for 4 weeks
Number of subjects: 24
Study 565216 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (Semet‐Se)
Number of subjects: 24
Study 565216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (selenite‐Se)
Number of subjects: 24
Study 31414860 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (n = 40)
Number of subjects: 80
Study 31414860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study 29745298 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protocol using TICCS for treatment guidance
Number of subjects: 0
Study 29745298 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 27515804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 54
Study 27515804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26142493 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview EVO2 video laryngoscope
Number of subjects: 42
Study 26142493 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 42
Study 24314930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus Medis 5 mg
Number of subjects: 36
Study 24314930 — intervention group
Group type: COMPARATOR
Intervention: Prograf® 5 mg
Number of subjects: 36
Study 21806769 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine/HCTZ 160/5/25 mg
Number of subjects: 488
Study 21806769 — intervention group
Group type: COMPARATOR
Intervention: Losartan/HCTZ 100/25 mg
Number of subjects: 488
Study 21806769 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine/HCTZ 320/10/25 mg (after titration)
Number of subjects: 488
Study 21806769 — intervention group
Group type: COMPARATOR
Intervention: Losartan/HCTZ switched to valsartan/amlodipine/HCTZ
Number of subjects: 488
Study 21806769 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine group
Number of subjects: 488
Study 21806769 — intervention group
Group type: COMPARATOR
Intervention: Losartan group
Number of subjects: 488
Study 19114918 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32-33 degrees C) for 48 hours
Number of subjects: 28
Study 19114918 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 28
Study 16930934 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment for 6 months
Number of subjects: 42
Study 16930934 — intervention group
Group type: COMPARATOR
Intervention: Subclinical hypothyroidism patients
Number of subjects: 42
Study 15517750 — intervention group
Group type: EXPERIMENTAL
Intervention: SurePress Comfort compression stocking
Number of subjects: 0
Study 15517750 — intervention group
Group type: COMPARATOR
Intervention: Standard short-stretch bandage (Comprilan)
Number of subjects: 0
Study 11742966 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 3
Study 9409548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg)
Number of subjects: 25
Study 9409548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8496313 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA; 20 mg/day) with GnRH analog (leuprolide acetate; 1 mg/day, sc)
Number of subjects: 16
Study 3427250 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled drinking self-help manual
Number of subjects: 0
Study 3427250 — intervention group
Group type: COMPARATOR
Intervention: General advice and information booklet
Number of subjects: 0
Study 3427250 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 0
Study 31603012 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (TT4): oral dexamethasone 40 mg for days 1-4, oral cyclosporine A 2–3 mg/kg daily for 28 consecutive days, intravenous rituximab 100 mg for days 7, 14, 21, and 28
Number of subjects: 40